

# Wesley R Armstrong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6783049/publications.pdf>

Version: 2024-02-01

12  
papers

544  
citations

840776  
11  
h-index

1199594  
12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

536  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Sink Effect in <sup>68</sup> Ga-PSMA-11 PET: Myth or Reality?. Journal of Nuclear Medicine, 2022, 63, 226-232.	5.0	42
2	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Journal of Nuclear Medicine, 2022, 63, 76-80.	5.0	20
3	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4271-4281.	6.4	38
4	The Impact of Monosodium Glutamate on <sup>68</sup> Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study. Journal of Nuclear Medicine, 2021, 62, 1244-1251.	5.0	10
5	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. European Urology Focus, 2021, 7, 238-240.	3.1	31
6	Prospective phase 2 trial of PSMA-targeted molecular Radiotherapy with <sup>177</sup> Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. Journal of Nuclear Medicine, 2021, 62, 1440-1446.	5.0	37
7	Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup> Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). Journal of Nuclear Medicine, 2021, 62, 1447-1456.	5.0	14
8	Nomograms to predict outcomes after <sup>177</sup> Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncology, The, 2021, 22, 1115-1125.	10.7	120
9	Diagnostic Accuracy of <sup>68</sup> Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncology, 2021, 7, 1635.	7.1	138
10	Total-Body <sup>68</sup> Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. Journal of Nuclear Medicine, 2020, 61, 405-411.	5.0	36
11	Accuracy of <sup>68</sup> Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study.. Journal of Clinical Oncology, 2020, 38, 5502-5502.	1.6	18
12	Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6842-6847.	7.1	40